Lawmakers Grill Pharma Execs on Trump's Drug Pricing Deals

Bipartisan committee demands transparency on 'Most Favored Nation' negotiations

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

A bipartisan group of lawmakers held a hearing to push for greater transparency on how former President Donald Trump brokered 'Most Favored Nation' drug pricing deals with top pharmaceutical companies. While the Trump administration launched a website offering discounted prescriptions, lawmakers raised concerns that many details of the negotiations have not been made public, and questioned whether the deals will truly benefit consumers.

Why it matters

The hearing highlights ongoing debates around drug pricing and the role of government in negotiating prescription costs. Lawmakers are seeking accountability for how the Trump administration reached these deals, which could have significant impacts on consumer access to affordable medications.

The details

The hearing was held by the House Energy and Commerce Committee, with both Republican and Democratic lawmakers pressing pharmaceutical industry leaders for more information. Witnesses like law professor Rachel Sachs testified that basic details like which drugs are included, the agreed-upon prices, and enforcement mechanisms remain unclear. PhRMA CEO Lori Reilly acknowledged they would 'have to take their word for it' that the deals benefit consumers, which drew criticism from Rep. Frank Pallone (D-NJ) as 'unacceptable'.

  • The Trump administration launched the TrumpRx.com website offering discounted prescriptions on February 11, 2026.
  • The congressional hearing was held on February 9, 2026, just days after the website launch.

The players

Rachel Sachs

A law professor at Washington University in St. Louis, Missouri, who testified at the hearing.

Lori Reilly

The CEO of PhRMA, the pharmaceutical industry trade group, who testified at the hearing.

Frank Pallone

A Democratic Congressman from New Jersey and the ranking member of the House Energy and Commerce Committee, who criticized the pharmaceutical industry's lack of transparency.

Got photos? Submit your photos here. ›

What they’re saying

“We don't know basic things like which drugs are included, what the agreed-upon prices are, and to whom they will be available? And how does the government have any ability to detect and enforce violations of these agreements?”

— Rachel Sachs, Law Professor

“It's absurd for me to take the word for it. I mean, that's not what we do. We don't take the word for anybody. We question, we do oversight, we look into it.”

— Frank Pallone, U.S. Congressman

What’s next

The House Energy and Commerce Committee is expected to continue its oversight of the Trump administration's drug pricing negotiations and the TrumpRx website in the coming weeks.

The takeaway

This hearing underscores the ongoing partisan battles over drug pricing and the role of government in regulating the pharmaceutical industry. While the Trump administration touted its efforts to lower drug costs, lawmakers from both parties are demanding more transparency to ensure any deals truly benefit consumers.